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Long-Term Perfusion of 
the Liver Outside the Body: 
Warming Up for Ex Vivo 
Therapies?
The term “game-changing technology” is every so 
often used as a hyperbole to underline the importance 
of research to the outside world. The experimental 
work of the ETH Zurich and University Hospital 
Zurich, recently published in Nature Biotechnology by 
Eshmuminov et al.,(1) is, however, no less than a real 
game changer in the field of liver transplantation. The 
authors achieved an increase in stable liver function ex 
vivo from a few hours to 7 days using a normothermic 
machine perfusion (NMP) device. This leap forward 
in perfusion time, while maintaining physiological bal-
ance, is incredibly important as it opens a window of 
opportunity to explore ex vivo organ repair therapies.
Driven by organ shortage and waiting list mor-
tality, transplant physicians are pushed to use donor 
organs of marginal quality. NMP provides opportu-
nities to test and even improve the quality of these 
grafts. However, with current commercially available 
NMP devices, safe perfusion is only warranted for up 
to 24 hours. In most clinically used perfusion proto-
cols, the portal vein is perfused with highly oxygen-
ated blood, resulting in a high demand for vasodilator 
medication. Furthermore, the perfusion systems lack 
sufficient physiological support, which is detrimental 
for long-term perfusion of donor livers. Obviously, 
in vivo, the liver is not an autonomous organ. Liver 
homeostasis depends on hormonal systems, such as 
pancreatic glucose regulation and kidney filtration to 
remove waste products, to regulate electrolyte levels, 
extracellular volume, and pH balance. Furthermore, 
motion created by the contraction of the diaphragm 
aids in perfusing the liver and provides biomechanical 
support for the functioning of the liver.
To achieve sustained ex vivo perfusion, in vivo phys-
iological conditions were mimicked. Glucose levels 
were monitored in real time, and glucose homeostasis 
was automatically regulated by administering glucose, 
insulin, or glucagon. Furthermore, an integrated dial-
ysis system continuously removed waste products and 
maintained electrolyte levels. Diaphragm movement 
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was simulated by inflation of a balloon under the liver, 
functioning like an antidecubitus bed and preventing 
nonperfused areas. Finally, oxygen saturation in the 
portal vein was set to the physiological venous satu-
ration, resulting in a decreased need for vasodilators. 
This article is not the first to implement these indi-
vidual components as, for example, hemodialysis and 
management of glucose homeostasis have been imple-
mented by others.(2,3) However, this article is the first 
to implement all of these different elements together 
in one automated circuit.
With the new perfusion system, 10 discarded human 
livers were perfused. In six of these livers, physiological 
levels of glucose, electrolytes, and oxygen saturation 
were maintained. These livers were found viable at 7 
days on the basis of adequate response to hormones 
and vasoactive agents and maintained histological 
integrity without endothelial activation and assessment 
of liver function/damage. During perfusion, a gradual 
decrease in nonviable cells was detected, and dividing 
cells were seen, indicating regeneration. Furthermore, 
glucose metabolism was preserved as determined by 
positron emission tomography/computed tomography 
imaging. This also revealed that these livers were fully 
perfused, without poorly perfused areas. Additionally, 
the metabolic and excretory liver functions were active 
throughout the perfusion as demonstrated by produc-
tion of adenosine triphosphate, coagulation factor V, 
urea, and bile. Metabolic products such as lactate and 
ammonia were efficiently cleared. The other four liv-
ers were found to be nonviable as they did not meet 
the viability score and showed insufficient metabolic 
or excretory liver function.
The lack of knowledge on how the viability scores 
should be valued as predictive values for successful and 
safe liver transplantation is a limitation. Porcine livers 
were functional after transplantation, but follow-up 
was only 3 hours. The ultimate proof would be clin-
ical transplantation of a human liver. Transplantation 
of a perfused human liver in an immune-incompetent 
porcine model could serve as an intermediate step for 
showing the safety of the procedure.
The novelty of this exciting publication does not lie 
within the possibility of testing liver function as an aid 
to deciding whether marginal or even discarded futile 
grafts can be used safely as this is also feasible during 
short-term (4-8 hours) NMP.(4) However, more time 
is required to sufficiently repair grafts on the pump. 
Clinical data from small-for-size living donor liver 
transplantation and the associated liver partition and 
portal vein ligation for staged hepatectomy procedure in 
extreme liver resections show that 5-7 days are needed 
to allow for sufficient cell proliferation and resumption 
of normal metabolic homeostasis by the liver.(5) Long-
term stable perfusion can provide clinicians with enough 
time to improve those grafts which do not pass the 
required criteria for short-term NMP. Furthermore, this 
repair process can be aided by applying exogenous repair 
therapies. 
These exogenous repair therapies or regenerative 
medicine strategies could include (stem) cell therapy 
or pharmacological interventions. An example of cell 
therapy is the infusion of mesenchymal stromal cells 
(MSCs) into the liver during perfusion, permitting 
the cells to engraft and exert their paracrine effects.(6) 
MSCs are shown to produce growth factors and 
interleukins, which benefit regeneration and reduce 
inflammation and hepatic injury.
Moreover, long-term NMP could be used to treat 
steatotic grafts with a “defatting cocktail,” to reduce 
steatosis and associated inflammation before trans-
plantation.(7) Severe steatosis is the main indication 
for declining donor livers as these livers are highly sus-
ceptible to reperfusion injury and primary nonfunc-
tion. Therefore, the increasing obesity of the donor 
population is a growing threat to liver transplanta-
tion. Being able to remove the fat from these grafts 
could enlarge the pool of suitable donor organs. Other 
potential applications could include a small liver graft 
incubator for a living donor or ex vivo complex liver 
resections or treatment of diseased liver (e.g., primary 
liver cancer) for improving treatment strategies.
The challenge ahead will be to translate from this 
excellent experimental work to clinical practice and to 
select patients who will benefit, while the technique is 
still in an experimental phase. If a donor liver is primar-
ily acceptable for transplantation, subjecting this liver 
to the long-term NMP platform might jeopardize an 
otherwise successful transplantation. If a liver graft fails 
to pass short-term NMP testing and needs long-term 
repair, is it justifiable to subject a patient to the risk of 
receiving this “refurbished” liver, while there is still time 
to wait for another primarily acceptable offer? Obviously, 
these decisions will be dictated by waiting list mortality 
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and dropout rates per center/country. Theoretically, 
patients who potentially benefit the most are those with 
very high Model for End-Stage Liver Disease scores or 
acute liver failure. However, these patients may not have 
the time to wait for the repair process and are the least 
able to cope with perioperative or posttransplant com-
plications, such as reperfusion syndrome, acute kidney 
injury, or delayed graft function. Given the sometimes 
troublesome graft reperfusion after short-term NMP 
(A. Schlegel to J. de Jonge, personal communication), 
not including these patients might initially be better. A 
logical choice would be to include patients with hepato-
cellular carcinoma threatening to cross transplantability 
criteria with otherwise stable liver disease or patients 
being denied access to liver transplantation (due to age, 
medical history of malignancy, etc.). In those cases, it 
should be clear if emergency retransplantation will be 
allowed in case of primary nonfunction.
Summarizing, this novel platform for ex vivo long-
term NMP of human livers provides an exciting ther-
apeutic playfield and is one of the most significant 
breakthroughs in hepatobiliary and transplant surgery 
of recent decades, enabling organ repair and regenera-
tive therapy on the pump.
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